Free Trial
NASDAQ:LNSR

LENSAR Q1 2025 Earnings Report

LENSAR logo
$12.92 -0.11 (-0.84%)
Closing price 08/12/2025 04:00 PM Eastern
Extended Trading
$12.90 -0.03 (-0.19%)
As of 08/12/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENSAR EPS Results

Actual EPS
-$2.32
Consensus EPS
-$0.16
Beat/Miss
Missed by -$2.17
One Year Ago EPS
N/A

LENSAR Revenue Results

Actual Revenue
$11.53 million
Expected Revenue
$13.40 million
Beat/Miss
Missed by -$1.87 million
YoY Revenue Growth
N/A

LENSAR Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

LENSAR's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

LENSAR Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More LENSAR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email.

About LENSAR

LENSAR (NASDAQ:LNSR), a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

View LENSAR Profile

More Earnings Resources from MarketBeat